Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

ATLANTA, March 12 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company focused on development of an HIV/AIDS vaccine, today announced its financial results for the fourth quarter and year ended December 31, 2008, and provided a summary of recent operational highlights for calendar year 2009 to date.

GeoVax reported a net loss of $1,039,217 for the fourth quarter ended December 31, 2008, as compared to a net loss of $1,155,870 for the comparable period in 2007. For the full year of 2008, the Company reported a net loss of $3,728,187 as compared to a net loss of $4,241,796 in 2007. GeoVax's operating results fluctuate due to the timing of activities and related costs associated with its vaccine research and development activities. Summarized financial information is presented below. GeoVax's full set of audited financial statements are included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Robert T. McNally, Ph.D., GeoVax's president and chief executive officer, stated, "For a company of GeoVax's size and stage of clinical development, our financial position is on target. Our operational expenses are reduced by the National Institutes of Health's (NIH) support of our ongoing Phase 2a preventative clinical trial being conducted by the HIV Vaccine Trials Network (HVTN), and are further offset by the direct grant from the NIH to GeoVax, covering research and development for future vaccine improvements. Our financial security is enhanced by the common stock purchase agreement with Fusion Capital Fund II, LLC. These funds are providing the Company with resources to conduct its own clinical trial in HIV infected, drug controlled subjects. Planning for this therapeutic trial is underway with a projected start for later this year."

            Recent Operational Highlights for Year 2009 - to date

    
'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
2. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
3. GeoVax to Present at the BIO CEO & Investor Conference 2009
4. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
5. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
8. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
9. GeoVax Further Strengthens Management Team
10. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will ... Align Technology, on “ Conducting Postmarket Registries - Rationale ... Conference and Exhibition on April 25th through April 28th ... poster presentation, Ale Gicqueau and Victor Chen will discuss ... the requirements and resources to conduct the registry, as ...
(Date:3/25/2015)... , March 25, 2015 Optimal Research, ... Vaccine Industry Excellence (ViE) Award "Best Clinical Site or ... year that Optimal has been selected as a nominee ... Congress, receiving a "Highly Recommended" distinction in 2014. The ... of the efforts, accomplishments, and positive contributions of companies ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... MN (PRWEB) March 25, 2015 ... breakthrough in nanoparticle technology that will enable broader ... many other diseases with a simple breath screen. ... on the U.S. Food and Drug Administration (FDA) ... launch of the innovative Nanoparticle Biomarker Tagging device. ...
Breaking Biology Technology:Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... will result in over $80 million reduction in 2009 ... Pharmaceuticals,Inc. (Nasdaq: AMLN ) today announced a corporate ... 25 percent, or 340,employees, and reduce anticipated 2009 cash ... reduction are part of the,Company,s business plan to be ...
... 10 Spherix Incorporated,(Nasdaq: SPEX ) reported that ... the listing of its common stock from the Nasdaq,Global ... is expected to,commence trading on the Nasdaq Capital Market ... is one of three market tier designations for,Nasdaq-listed stocks, ...
... TRBN ) announced today financial results for its third ... Quarter and Nine Months Financial Results, Revenue for ... 2008, was,$3.8 million and $12.2 million respectively, compared with ... the third quarter and nine,months ended Sept. 30, 2008, ...
Cached Biology Technology:Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 2Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 3Spherix Transfers Stock Listing to Nasdaq Capital Market 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... of the "Access Control Market by Product, Application ... 2020" report to their offering. , ... expected to reach $10.4 billion by 2020, with an ... market report covers the products types such as contact ...
(Date:3/10/2015)... 2015   Tute Genomics , pioneer in affordable, ... next-generation sequencing company PrimBio Research Institute to ... gene panel interpretation. PrimBio, a certified Life ... current technologies to support the work of experts on ... two types of exome sequencing services: 1) Targeted Exome ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... countless coral reefs around the world can now be nabbed ... say. Coral researchers and reef managers will be able ... them to classify specific diseases based on the presence of ... reduce the impact of disease on the world,s imperilled coral ...
... Alto, CA--The four largest nonprofit plant science research institutions ... Association of Independent Plant Research Institutes (AIPI) in an ... profound challenges facing society in a more coordinated and ... Thompson Institute for Plant Research (Cornell University), The Carnegie ...
... for athletes looking to boost performance comes in the form ... reason for its popularity is twofold says Scott Forbes, a ... precursor for nitric oxide that is known to improve blood ... nutrients to working muscles and assist with metabolic waste product ...
Cached Biology News:Scientific sleuths pinpoint the guilty coral killers 2Big boost to plant research 2Big boost to plant research 3L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3
...
... MS/MS analysis & visualization ... across multiple samples. Combine ... for increased confidence. Get ... information from your MS/MS ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: